Indivior Pharmaceuticals, Inc. (INDV) News
Follow Indivior Pharmaceuticals, Inc. (INDV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Indivior Shares Rise After Q3 Adjusted EPS and Revenue Top Estimates
Indivior shares were up more than 4% after the company’s Q3 adjusted EPS and revenue topped estimates.
EQUITY | Oct 29, 2026, 01:54 PM UTC
M
Indivior Reports Third-Quarter 2026 Revenue of $356 Million
Revenue rose 13.4% from $314 million a year earlier. Net income increased to $137 million from $42 million, and diluted EPS rose to $1.12 from $0.33.
EQUITY | Oct 29, 2026, 12:21 PM UTC
M
Indivior Expects 2026 Revenue of $1.30B-$1.37B
Indivior expects 2026 net revenue of $1.30 billion to $1.37 billion, versus a FactSet estimate of $1.33 billion.
EARNINGS | Oct 29, 2026, 11:51 AM UTC
M
Indivior Reports Third-Quarter Revenue of $356 Million
EQUITY | Oct 29, 2026, 11:34 AM UTC
M
Indivior Q3 net income more than triples to $137 million
EARNINGS | Oct 29, 2026, 11:12 AM UTC
M
Indivior Reports Q3 Revenue of $356.0 Million
Indivior reported Q3 revenue of $356.0 million, versus a FactSet estimate of $329.4 million.
EQUITY | Oct 29, 2026, 11:07 AM UTC
M
Indivior Posts Q3 Adjusted EPS of $1.32 vs. $1.06 Estimate
Indivior reported Q3 adjusted EPS of $1.32 per share, compared with a FactSet estimate of $1.06.
EARNINGS | Oct 29, 2026, 11:07 AM UTC
M
Indivior Sees 2026 Revenue of $1.3B-$1.37B
EARNINGS | Oct 29, 2026, 11:07 AM UTC
M
Indivior to report third-quarter 2026 results
EQUITY | Oct 19, 2026, 12:30 PM UTC
L
INDV - Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
INDV - Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
NEWS | Sep 17, 2026, 11:23 AM UTC
M
Indivior to end Reckitt copacker supply deal by Jan 15, 2027
Indivior entered a Deed of Variation and Termination with Reckitt Benckiser Healthcare to accelerate the end of their Copacker Supply Agreement for SUBOXONE and SUBUTEX tablets to January 15, 2027, with RB continuing man
MNA | Sep 15, 2026, 08:34 PM UTC
L
Indivior, Supernus announce proposed all-stock merger
Indivior and Supernus say they will combine in an all-stock, tax-free merger of equals, with expected annual cost synergies of $125 million.
EARNINGS | Aug 17, 2026, 09:19 AM UTC
L
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Aug 04, 2026, 10:04 AM UTC
L
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmace
EARNINGS | Aug 03, 2026, 02:44 PM UTC
H
Supernus, Indivior Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader
MNA | Aug 03, 2026, 12:26 PM UTC
L
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est
Indivior Pharmaceuticals (NASDAQ: INDV ) raises FY2026 sales outlook from $1.215 billion-$1.285 billion to $1.295 billion-$1.365 billion vs $1.245 billion estimate.
EARNINGS | Aug 03, 2026, 10:45 AM UTC
H
Indivior Buys Supernus
Indivior acquires Supernus in stock deal
MNA | Aug 03, 2026, 10:35 AM UTC
H
SUPN, INDV Agree Merger
SUPN and INDV agree to merge
MNA | Aug 03, 2026, 10:33 AM UTC
L
INDV - Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
INDV - Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
EARNINGS | Aug 03, 2026, 10:31 AM UTC